Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05463796 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05463796 · ClinicalTrials.gov record · last posted 2026-08-17

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

StatusRecruiting
PhaseNot specified
Started2023-04-25
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

Protocol amendment history 2 changes detected by DataLookout

2026-08-18
Primary completion pushed: 2027-03-25 → 2030-03-25
2026-08-18
Completion moved earlier: 2032-03-25 → 2031-03-25
Trial Details
NCT Number NCT05463796
Lead Sponsor Dana-Farber Cancer Institute
Conditions Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer +23 more
Enrollment 5,000 participants
Start Date 2023-04-25
Primary Completion 2030-03-25 (estimated)
Study Completion 2031-03-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-17